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Objective: Criteria for selecting patients to receive adjuvant chemotherapy in cases of resected
intrahepatic or hilar cholangiocarcinoma (CC) are lacking. Some clinicians advocate the provision of
adjuvant therapy in patients with lymph node (LN)-positive disease; however, nodal assessment is often
inadequate. The aim of this study was to identify a surrogate criterion based on primary tumour
characteristics.
Methods: All patients who underwent resection for hilar or intrahepatic CC at a single institution between
January 2000 and September 2009 were identified from a prospectively maintained database. Patho-
logical factors were recorded. The primary outcome assessed was overall survival (OS).
Results: In total, 69 patients underwent resection for hilar (n = 34) or intrahepatic (n = 35) CC. Their
median age was 66 years and 27 patients (39%) were male. Median follow-up was 22 months and median
OS was 17 months. Median tumour size was 5 cm. Overall, 23% of patients had a positive resection
margin, 44% had perineural invasion, 32% had lymphovascular invasion (LVI) and 25% had positive LNs.
The median number of LNs removed was two and the median number of positive LNs was zero. The
presence of LVI was associated with reduced OS (11.9 months vs. 23.1 months; P = 0.023). After
accounting for all other adverse tumour factors, the presence of LVI persisted as the only negative
prognostic factor for OS on multivariate Cox regression.
Conclusions: In patients who had undergone resection of hilar or intrahepatic CC, the presence of LVI
was strongly associated with reduced OS. Thus the finding of LVI may potentially be used as a criterion
in the selection of patients for adjuvant chemotherapy.
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Introduction
Cholangiocarcinoma (CC) is an uncommon malignancy that
affects approximately 5000 individuals per year in the USA.1
Although CC is a rare tumour, it is the second most common
primary hepatic malignancy after hepatocellular carcinoma and
globally accounts for 3% of all gastrointestinal malignancies.2
Because of its aggressive behaviour and modest response to
current chemotherapy regimens, longterm survival is poor and
tumour incidence nearly equals mortality rates.
Cholangiocarcinomas are divided into three general categories
based on their anatomic location of origin. Intrahepatic CC
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arises from within the hepatic parenchyma and accounts for
approximately 20% of all CCs; the incidence of this category
seems to be on the rise.3,4 Hilar CCs are the most common form
(50–60%) and occur at the confluence of the hepatic ducts; the
remaining 20–30% of CCs are categorized as distal CCs and
often arise from within the intrapancreatic portion of the
common bile duct.3 Complete resection remains the mainstay of
therapy and represents the only opportunity for cure. Unfortu-
nately, nearly 75% of patients present with unresectable disease,
for which chemotherapy offers a median survival of only 5–8
months.5,6 In patients with resectable disease, however, 5-year
survival rates remain at only 35–45%.7 Efforts to improve sur-
vival have included the administration of adjuvant chemo-
therapy, but this has met with limited success and its potential
effectiveness is likely to be largely dependent on appropriate
patient selection. Based on the recent Advanced Biliary
Cancer (ABC-02) Trial, a doublet chemotherapy regimen con-
sisting of gemcitabine (Gem) with concurrent cisplatin (Cis) has
emerged as the standard of care for advanced CC as patients
receiving this therapy showed improved median overall survival
(OS) compared with those who received Gem monotherapy
(11.7 months vs. 8.1 months; P < 0.001).8 Currently, there are
minimal data to guide the use of adjuvant chemotherapy
after complete resection, especially as previous regimens were
marginally effective and have not been shown to be beneficial in
the adjuvant setting.9,10 The ABC-02 Trial provides us with
a new and more effective regimen (Gem/Cis) that may poten-
tially be utilized also after resection. Selection criteria, however,
for offering chemotherapy after resection are not standardized
for CC.
Many studies have investigated prognostic factors associated
with poor survival after resection of CC. One of the key patho-
logical factors consistently associated with poor survival is
lymph node (LN)-positive disease.11–13 The American Joint Com-
mittee on Cancer (AJCC) utilizes LN involvement in addition to
vascular invasion, presence of multiple tumours and metastatic
disease for the staging of intrahepatic CC.14 Lymph node-
positive disease is frequently used as a selection criterion for
adjuvant chemotherapy. Similarly, several studies have found
LN-positive disease to be a poor prognostic factor for survival in
patients with hilar CC.15–17 Although the current classification
system does provide some information with regard to LN
involvement and longterm prognosis, there is no standard guide-
line for the number of nodes that must be retrieved to ensure
accurate staging, probably because the porta hepatis typically
harbours very few LNs. Furthermore, portal lymphadenectomy
(LAD) is not routinely performed for intrahepatic CC. Thus, the
median number of LNs retrieved during resection of hilar or
intrahepatic CC is often minimal to none. The aim of this
study was to identify a surrogate marker for adverse tumour
biology based on the primary tumour that might be used as
an alternative criterion in the selection of patients for adjuvant
chemotherapy.
Materials and methods
A prospectively maintained hepatobiliary surgery database at the
Winship Cancer Institute at Emory University was reviewed for all
patients with a diagnosis of intrahepatic or hilar CC who under-
went resection between January 2000 and September 2009.
Patients with advanced disease or those diagnosed with distal CC
were excluded from analysis. Permission from Emory University’s
Institutional Review Board was obtained prior to data review, and
Health Insurance Portability and Accountability Act (HIPAA)
compliance was ensured.
A total of 69 patients who underwent resection were identified.
Overall survival was ascertained using the clinical follow-up data
documented in each patient’s medical record and the Social Secu-
rity Death Index. Pathology reports were reviewed for important
tumour factors that are known to have prognostic value for
patient survival. Specifically, data on tumour size, number, margin
status, LN involvement, presence of lymphovascular invasion
(LVI) and perineural invasion (PNI) were recorded.11,18,19
Statistical analysis
Data were analysed using spss Version 17.0 for Windows (SPSS,
Inc., Chicago, IL, USA). Kaplan–Meier log-rank survival analysis
was used to determine the association of each pathological factor
with patient survival. Multivariate Cox regression analysis of
adverse tumour factors was performed to determine which patho-
logical variables were independently associated with decreased
OS.
Results
Clinicopathological variables and postoperative outcomes are
shown in Table 1. The median number of LNs retrieved was three
(range: 0–24) in hilar CC and one (range: 0–10) in intrahepatic
CC (P = 0.004). There was no statistical difference in the frequency
of LN positivity between hilar and intrahepatic CC patients (32%
vs. 17%, respectively; P = 0.17). The median number of positive
LNs in both hilar and intrahepatic CC was zero (hilar: range 0–3;
intrahepatic: range 0–2; P = 0.146).
Survival analysis
The median length of follow-up for survivors was 22 months
(range: 0.5–81.4 months). At the time of last follow-up, 46
patients (67%) had died. Median OS for all patients was 17.3
months (range: 0.3–81.4 months). Kaplan–Meier survival analysis
of known prognostic factors revealed the presence of LVI to be the
only adverse pathological factor significantly associated with
reduced survival (Fig. 1A–E). A subset analysis of only those
patients with LN-negative disease or those in whom no LNs were
assessed (n = 52) demonstrated a strong trend towards reduced
survival in patients whose tumours were positive for LVI (Fig. 2).
Tumour grade was not statistically associated with poor survival
(median OS: well, 28.3 months; moderate, 20.3 months; poor, 14.4
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months; P = 0.958). There was no association between LN posi-
tivity and presence of LVI (LN-pos/LVI-pos: 10%; LN-neg/LVI-
pos: 22%; P = 0.344). After accounting for all other adverse
tumour factors in a multivariate Cox regression analysis, the pres-
ence of LVI exhibited the strongest association with reduced sur-
vival (Table 2).
Discussion
The purpose of this study was to identify a surrogate marker for
adverse tumour biology based on the primary tumour that might
be used as an alternative criterion in the selection of patients for
adjuvant chemotherapy. Cholangiocarcinoma is a deadly disease
responsible for approximately 5000 deaths in the USA per year.
Although surgery remains the mainstay of treatment, nearly 75%
of patients present with unresectable disease.5,6 Based on data
from the ABC-02 Trial, combination systemic chemotherapy with
Gem/Cis has replaced Gem monotherapy as the standard of care
for advanced CC, giving a median OS of 11.7 months vs. 8.1
months (P < 0.001).8 Prospective studies supporting the use of
adjuvant chemotherapy after resection are scarce.10,20,21 It may be
that the Gem/Cis combination will also prove beneficial in the
adjuvant setting, but this is likely to depend on proper patient
selection.
In this study, intrahepatic and hilar CCs were examined
together. Although hilar and intrahepatic CCs probably represent
two distinct entities, they share many similarities in terms of their
clinical management and whether or not adjuvant chemotherapy
is given after resection. Firstly, resection is the primary modality of
treatment in both processes and, secondly, the decision to admin-
ister adjuvant chemotherapy is largely based on the presence of
adverse tumour factors, namely, LN-positive disease. Recently, the
International Intrahepatic Cholangiocarcinoma Study Group
(IICSG) presented its findings on adverse prognostic factors in
intrahepatic CC and recommended that routine portal LN dissec-
tion should be performed along with resection of the primary
tumour.22 Thus, based on this recommendation, intrahepatic and
hilar CC should be surgically treated in the same manner, namely,
by resection of the primary tumour and portal lymphadenectomy.
Furthermore, in the recently published ABC-02 Trial, intrahe-
patic, hilar and distal CCs were grouped together with gallbladder
and ampullary cancer to assess the efficacy of Gem/Cis compared
with Gem monotherapy for biliary cancers.8 If medical oncolo-
gists design randomized studies that group all these different
disease types together in order to establish clinical guidelines for
the treatment of all biliary tract malignancies as if they repre-
sented one entity, then it is not unreasonable to group a subset of
these disease types to study their indications for the same adjuvant
therapy.
Currently, adverse tumour-related pathological factors, such as
a positive resection margin, LN involvement, PNI and vascular
invasion, are sometimes used as indications for adjuvant systemic
therapy.21 Of these factors, LN involvement is the most widely
Table 1 Clinicopathological data for patients undergoing resection
for cholangiocarcinoma (n = 69)
Clinical variables n (%) Median (range)
Age, years 66 (32–82)
Gender
Male 27 (39%)
Female 42 (61%)
Race
White 53 (77%)
Black 7 (11%)
Hispanic 1 (1%)
Asian 1 (1%)
Other 7 (10%)
ASA score
1 1 (1%)
2 5 (7%)
3 21 (31%)
4 2 (3%)
Unknown 40 (58%)
Hypertension 39 (57%)
Diabetes 14 (20%)
ETOH abuse 7 (10%)
Smoking 17 (25%)
Operative variables
Estimated blood loss, ml 500 (50–4000)
Type of resection
Left hepatectomy 22 (33%)
Left lateral sectorectomy 4 (6%)
Left trisegmentectomy 2 (3%)
Extended left hepatectomy 5 (8%)
Right hepatectomy 10 (16%)
Right trisegmentectomy 9 (14%)
Extended right hepatectomy 11 (16%)
Central hepatectomy 2 (3%)
Liver transplantation 1 (1%)
Pathology variables
Positive resection margin 16 (23%)
Tumour size, cm 5 (1–21)
Number of lesions 1 (1–2)
Tumour size  5 cm 37 (54%)
Lymphovascular invasion 22 (32%)
Perineural invasion 30 (44%)
Lymph node-positive disease 17 (25%) 0 (0–3)
Number of nodes retrieved 2 (0–24)
Postoperative course
Length of hospital stay, days 10 (1–55)
30-day mortality 7 (10%)
Complications 38 (55%)
Infectious complication 22
Bleeding 2
Bile leak 4
Pulmonary embolism 1
Re-operation 5
ASA, American Society of Anesthesiologists; ETOH, ethanol.
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Figure 1 Adverse tumour markers and overall survival (OS) in resected intrahepatic or hilar cholangiocarcinoma (n = 69) showing associa-
tions between OS and (A) tumour size (P = 0.212; tumour size  5 cm, n = 37; tumour size < 5 cm, n = 32), (B) a positive resection margin
(P = 0.790; margin positive, n = 16; margin negative, n = 53), (C) lymph node (LN)-positive disease (P = 0.098; LN-negative, n = 52;
LN-positive, n = 17), (D) perineural invasion (PNI) (P = 0.081; PNI-negative, n = 39; PNI-positive, n = 30) and (E) lymphovascular invasion (LVI)
(P = 0.023; LVI-negative, n = 47; LVI-positive, n = 22)
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recognized as associated with poor survival after resection, and is
currently the major criterion used to select patients for adjuvant
chemotherapy in intrahepatic or hilar CC.11,19,20,23
This study excluded gallbladder and ampullary cancers
because the authors consider that these should be regarded as
distinct entities when studying indications for adjuvant therapy.
Similarly, the resection of a distal CC is accompanied by LN
retrieval that is sufficiently adequate to enable the decision on
adjuvant therapy to be based on LN status; thus, this disease
entity was also excluded. However, intrahepatic and hilar CCs are
both limited by marginal LN retrieval because of the limited
number of LNs in the porta hepatis. This is especially true in
intrahepatic CC, in which complete portal lymphadenectomy is
not routinely performed. The IICSG reported that approximately
half of patients undergoing resection of intrahepatic CC under-
went a simultaneous lymphadenectomy and the median number
of LNs retrieved was only three.22 This practice pattern is likely to
stem from the fact that LN involvement delineates stage IV
disease, and thus removing the nodes offers only prognostic data
with minimal to no therapeutic benefit to the patient. Even in
hilar CC, although a complete portal LN dissection is a standard
component of the procedure, the total number of nodes retrieved
is often minimal. Although a study from the Memorial Sloan–
Kettering Cancer Center recommends retrieving at least seven
LNs for adequate staging of hilar CCs, the current AJCC classi-
fication system does not specify the number of LNs required,
mostly because the number retrieved is so minimal and vari-
able.24 The drastic variation and limitation in LN retrieval prob-
ably explain why the findings of series examining LN-positive
rates in resectable lesions range from 20–80%.10,25,26
In the present study, the median number of LNs retrieved in
hilar and intrahepatic CC was only two. In a limited subset analy-
sis, the median number of LNs retrieved during resection of hilar
CC was greater than that in intrahepatic CC (three vs. one; P =
0.004). Although this result is statistically significant, the clinical
significance of a difference of only two LNs is dubious. Accord-
ingly, the median number of positive LNs for both tumour types
was zero, suggesting that even when a few more LNs are recovered,
the rate of nodal involvement detected by standard pathological
techniques remains minimal to non-existent. A recent study by
Oshiro et al. investigating the prognostic value of LN ratio (LNR:
LNs positive : LNs retrieved) in extrahepatic CC found a median
LNR of zero, regardless of how many nodes were retrieved.27 Thus,
a surrogate criterion based on characteristics of the primary
tumour that may help to better select patients for adjuvant che-
motherapy after resection of hilar or intrahepatic CC is required.
This is especially important in light of the ABC-02 Trial results,
which show that a more effective chemotherapeutic regimen is
available for biliary tract malignancies.8
In the evaluation of adverse tumour markers, the presence of
LVI was the only factor to be significantly associated with short-
ened OS on both univariate Kaplan–Meier survival analysis and
multivariate Cox regression analysis. This finding of reduced
survival with positive LVI persisted in a subset analysis of
patients with LN-negative disease. Lymph node-positive disease,
a positive resection margin and PNI all exhibited trends towards
reduced OS, and thus it is possible that a larger sample size
might allow the associations between these adverse tumour
factors and reduced OS to reach significance. Tumour size of
<5 cm was also associated with a trend towards shortened OS.
This finding may be partly explained by the fact that the median
tumour size was greater in intrahepatic than in hilar CC (6.5 cm
vs. 3.0 cm; P < 0.001) and that patients with intrahepatic CC
had a slightly prolonged survival (17.3 months vs. 16.7 months;
P = NS).
That lymphatic and vascular invasion are important is not nec-
essarily a novel concept. Several studies have reported that, in
addition to LN positivity, the presence of vascular invasion is
strongly associated with shortened OS.28–30 It is intuitive to con-
sider LVI as a predecessor to LN-positive disease, and therefore a
surrogate marker of nodal disease. However, this study found no
association between LVI and LN positivity (P = 0.344). This lack of
association has also been confirmed in several studies examining
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Figure 2 Presence of lymphovascular invasion (LVI) and overall
survival in patients with lymph node-negative disease (n = 52)
(P = 0.079; LVI-negative, n = 37; LVI-positive, n = 15)
Table 2 Multivariate Cox regression analysis of adverse tumour
factors for overall survival (n = 69)
Variable HR 95% CI P-value
Tumour size  5 cm 0.64 0.33–1.28 0.208
Positive margin 1.27 0.60–2.68 0.532
Positive lymph node 1.80 0.89–3.61 0.102
Perineural invasion 1.40 0.73–2.69 0.309
Lymphovascular invasion 2.01 1.02–3.99 0.045
HR, hazard ratio; 95% CI, 95% confidence interval.
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nodal status and LVI in breast cancer.31,32 Additionally, LVI is a
broad term that encompasses either vascular invasion or lym-
phatic invasion, or both (lymphovascular invasion). Thus, a direct
correlation between the presence of LVI and LN-positive disease
may not always be apparent. Rather, LVI and LN involvement
seem to be independent poor prognostic factors for OS.
Along with its retrospective nature, the limitations of this study
include its small sample size. This prevented a meaningful subset
analysis to assess the prognostic value of LVI in hilar and intrahe-
patic CC individually. A multi-institutional investigation is nec-
essary to analyse a larger sample size and such a study is currently
underway. Nevertheless, from a clinical perspective, hilar and
intrahepatic CCs are managed similarly in that resection is the
mainstay of therapy and adjuvant chemotherapy is offered based
on pathological factors, of which LN involvement is currently the
most predominant.
Lymphovascular invasion is routinely assessed for each of these
tumours as part of a standard pathological evaluation and is not
subject to variability in LN retrieval during each operation. Addi-
tionally, given that the presence of LVI is strongly associated with
reduced OS, it may be a more reproducible criterion on which to
base the selection of patients for adjuvant chemotherapy after
complete resection of hilar or intrahepatic CC, particularly in
patients in whom LN status has been inadequately evaluated or
who have LN-negative disease.
Conflicts of interest
None declared.
References
1. Shaib Y, El-Serag HB. (2004) The epidemiology of cholangiocarcinoma.
Semin Liver Dis 24:115–125.
2. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. (2005) Cho-
langiocarcinoma. Lancet 366:1303–1314.
3. Malhi H, Gores GJ. (2006) Cholangiocarcinoma: modern advances in
understanding a deadly old disease. J Hepatol 45:856–867.
4. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D et al. (2008)
Intrahepatic cholangiocarcinoma: rising frequency, improved survival,
and determinants of outcome after resection. Ann Surg 248:84–96.
5. Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M et al.
(2008) Guidelines for the management of biliary tract and ampullary
carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg 15:41–54.
6. Chou F, Sheen-Chen S, Chen Y, Chen M, Chen C. (1997) Surgical
treatment of cholangiocarcinoma. Hepatogastroenterology 44:760–765.
7. Dingle BH, Rumble RB, Brouwers MC. (2005) The role of gemcitabine in
the treatment of cholangiocarcinoma and gallbladder cancer: a system-
atic review. Can J Gastroenterol 19:711–716.
8. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A
et al. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary
tract cancer. N Engl J Med 362:1273–1281.
9. Todoroki T. (2000) Chemotherapy for bile duct carcinoma in the light of
adjuvant chemotherapy to surgery. Hepatogastroenterology 47:644–649.
10. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H et al.
(2002) Is postoperative adjuvant chemotherapy useful for gallbladder
carcinoma? A phase III multicentre prospective randomized controlled
trial in patients with resected pancreaticobiliary carcinoma. Cancer
95:1685–1695.
11. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N
et al. (2011) Prognostic factors after surgical resection for intrahepatic,
hilar, and distal cholangiocarcinoma. Ann Surg Oncol 18:615–658.
12. Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T et al.
(2010) Surgery and chemotherapy for intrahepatic cholangiocarcinoma.
World J Hepatol 2:58–64.
13. Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S,
Takayama T et al. (2001) A new staging system for mass-forming intra-
hepatic cholangiocarcinoma: analysis of preoperative and postoperative
variables. Cancer 92:2374–2383.
14. Farges O, Fuks D, Le Treut YP, Azoulay D, Laurent A, Bachellier P et al.
(2011) AJCC 7th edition of TNM staging accurately discriminates out-
comes of patients with resectable intrahepatic cholangiocarcinoma: by
the AFC-IHCC-2009 study group. Cancer 117:2170–2177.
15. Allen PJ, Reiner AS, Gonen M, Klimstra DK, Blumgart LH, Brennan MF
et al. (2008) Extrahepatic cholangiocarcinoma: a comparison of patients
with resected proximal and distal lesions. HPB 10:341–346.
16. Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H et al.
(2001) Lymph node metastasis from hilar cholangiocarcinoma: audit of
110 patients who underwent regional and para-aortic node dissection.
Ann Surg 233:385–392.
17. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM,
Lillemoe KD et al. (2007) Cholangiocarcinoma: thirty-one-year experience
with 564 patients at a single institution. Ann Surg 245:755–762.
18. Hanazaki K, Kajikawa S, Shimozawa N, Shimada K, Hiraguri M, Koide N
et al. (2002) Prognostic factors of intrahepatic cholangiocarcinoma after
hepatic resection: univariate and multivariate analysis. Hepatogastroen-
terology 49:311–316.
19. Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A,
Nicoli P et al. (2009) Intrahepatic cholangiocarcinoma: prognostic factors
after surgical resection. World J Surg 33:1247–1254.
20. Yubin L, Chihua F, Zhixiang J, Jinrui O, Zixian L, Jianghua Z et al. (2008)
Surgical management and prognostic factors of hilar cholangiocarci-
noma: experience with 115 cases in China. Ann Surg Oncol 15:2113–
2119.
21. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura
H et al. (2009) Gemcitabine-based adjuvant chemotherapy improves sur-
vival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest
Surg 13:1470–1479.
22. Pawlik TM, Pulitano C, Alexandrescu S, Gamblin TC, Ferrone C,
Sotiropoulos G et al. Intrahepatic cholangiocarcinoma: an international,
multi-institutional analysis of prognostic factors and lymph node assess-
ment. Oral Abstract, Society of Surgical Oncology Meeting, San Antonio,
TX, 20–22 January.
23. National Comprehensive Cancer Network (NCCN). (2010) Clinical prac-
tice guidelines in oncology: hepatobiliary cancers; V. 2.2010. http://
www.nccn.org. [Accessed 29 February 2011.]
24. Ito K, Ito H, Allen PJ, Gonen M, Klimstra D, D'Angelica MI et al. (2010)
Adequate lymph node assessment for extrahepatic bile duct adenocar-
cinoma. Ann Surg 251:675–681.
25. Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD et al.
(2009) A proposed staging system for intrahepatic cholangiocarcinoma.
Ann Surg Oncol 16:14–22.
26. Shen WF, Zhong W, Xu F, Kan T, Geng L, Xie F et al. (2009) Clinicopatho-
610 HPB
HPB 2011, 13, 605–611 © 2011 International Hepato-Pancreato-Biliary Association
logical and prognostic analysis of 429 patients with intrahepatic cholan-
giocarcinoma. World J Gastroenterol 15:5976–5982.
27. Oshiro Y, Sasaki R, Kobayashi A, Murata S, Fukunaga K, Kondo T et al.
(2011) Prognostic relevance of the lymph node ratio in surgical patients
with extrahepatic cholangiocarcinoma. Eur J Surg Oncol 37:60–64.
28. Young AL, Prasad KR, Toogood GJ, Lodge JP. (2010) Surgical treatment
of hilar cholangiocarcinoma in a new era: comparison among leading
Eastern and Western centres, Leeds. J Hepatobiliary Pancreat Sci
17:497–504.
29. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH.
(2001) Intrahepatic cholangiocarcinoma: resectability, recurrence pattern,
and outcomes. J Am Coll Surg 193:384–391.
30. El Rassi ZE, Partensky C, Scoazec JY, Henry L, Lombard-Bohas C,
Maddern G. (1999) Peripheral cholangiocarcinoma: presentation,
diagnosis, pathology and management. Eur J Surg Oncol 25:375–
380.
31. Ragage F, Debled M, MacGrogan G, Brouste V, Desrousseaux M,
Soubeyran I et al. (2010) Is it useful to detect lymphovascular invasion in
lymph node-positive patients with primary operable breast cancer?
Cancer 116:3093–3101.
32. Woo CS, Silberman H, Nakamura SK, Ye W, Sposto R, Colburn W et al.
(2002) Lymph node status combined with lymphovascular invasion
creates a more powerful tool for predicting outcome in patients with
invasive breast cancer. Am J Surg 184:337–340.
HPB 611
HPB 2011, 13, 605–611 © 2011 International Hepato-Pancreato-Biliary Association
